Cargando…
Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group.
In the search for effective chemotherapy regimens which can be used in multimodality treatment programmes for patients with cancer of the oesophagus, we conducted a phase II trial to determine the activity and toxicity of the combination of cisplatin and etoposide in patients with advanced squamous...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074745/ https://www.ncbi.nlm.nih.gov/pubmed/8826870 |
_version_ | 1782138033781342208 |
---|---|
author | Kok, T. C. Van der Gaast, A. Dees, J. Eykenboom, W. M. Van Overhagen, H. Stoter, G. Tilanus, H. W. Splinter, T. A. |
author_facet | Kok, T. C. Van der Gaast, A. Dees, J. Eykenboom, W. M. Van Overhagen, H. Stoter, G. Tilanus, H. W. Splinter, T. A. |
author_sort | Kok, T. C. |
collection | PubMed |
description | In the search for effective chemotherapy regimens which can be used in multimodality treatment programmes for patients with cancer of the oesophagus, we conducted a phase II trial to determine the activity and toxicity of the combination of cisplatin and etoposide in patients with advanced squamous cell carcinoma of the oesophagus. Seventy-three consecutive patients with unresectable or metastatic squamous cell carcinoma of the thoracic oesophagus were treated with cisplatin 80 mg m-2 by 4 h infusion on day 1, etoposide 100 mg (fixed dose) by 2 h infusion on day 1 and 2, and etoposide 200 mg m-2 orally on day 3 and 5. Courses were repeated every 4 weeks, for a maximum of six courses. The oral dosages of etoposide were modified individually until a significant degree of myelosuppression was reached. Of 65 evaluable patients, five complete responses (CRs) and 26 partial responses (PRs) were seen, for an overall response rate of 48% (95% confidence interval 35-60%). Median time to progression was 7 months (range 3-72 + months). There were two toxic deaths (neutropenic sepsis). The response rate equals that of other cisplatin-based regimens. Its toxicity profile allows addition of a third active drug such as 5-fluorouracil. |
format | Text |
id | pubmed-2074745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1996 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20747452009-09-10 Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. Kok, T. C. Van der Gaast, A. Dees, J. Eykenboom, W. M. Van Overhagen, H. Stoter, G. Tilanus, H. W. Splinter, T. A. Br J Cancer Research Article In the search for effective chemotherapy regimens which can be used in multimodality treatment programmes for patients with cancer of the oesophagus, we conducted a phase II trial to determine the activity and toxicity of the combination of cisplatin and etoposide in patients with advanced squamous cell carcinoma of the oesophagus. Seventy-three consecutive patients with unresectable or metastatic squamous cell carcinoma of the thoracic oesophagus were treated with cisplatin 80 mg m-2 by 4 h infusion on day 1, etoposide 100 mg (fixed dose) by 2 h infusion on day 1 and 2, and etoposide 200 mg m-2 orally on day 3 and 5. Courses were repeated every 4 weeks, for a maximum of six courses. The oral dosages of etoposide were modified individually until a significant degree of myelosuppression was reached. Of 65 evaluable patients, five complete responses (CRs) and 26 partial responses (PRs) were seen, for an overall response rate of 48% (95% confidence interval 35-60%). Median time to progression was 7 months (range 3-72 + months). There were two toxic deaths (neutropenic sepsis). The response rate equals that of other cisplatin-based regimens. Its toxicity profile allows addition of a third active drug such as 5-fluorouracil. Nature Publishing Group 1996-09 /pmc/articles/PMC2074745/ /pubmed/8826870 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Kok, T. C. Van der Gaast, A. Dees, J. Eykenboom, W. M. Van Overhagen, H. Stoter, G. Tilanus, H. W. Splinter, T. A. Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. |
title | Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. |
title_full | Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. |
title_fullStr | Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. |
title_full_unstemmed | Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. |
title_short | Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. |
title_sort | cisplatin and etoposide in oesophageal cancer: a phase ii study. rotterdam oesophageal tumour study group. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074745/ https://www.ncbi.nlm.nih.gov/pubmed/8826870 |
work_keys_str_mv | AT koktc cisplatinandetoposideinoesophagealcanceraphaseiistudyrotterdamoesophagealtumourstudygroup AT vandergaasta cisplatinandetoposideinoesophagealcanceraphaseiistudyrotterdamoesophagealtumourstudygroup AT deesj cisplatinandetoposideinoesophagealcanceraphaseiistudyrotterdamoesophagealtumourstudygroup AT eykenboomwm cisplatinandetoposideinoesophagealcanceraphaseiistudyrotterdamoesophagealtumourstudygroup AT vanoverhagenh cisplatinandetoposideinoesophagealcanceraphaseiistudyrotterdamoesophagealtumourstudygroup AT stoterg cisplatinandetoposideinoesophagealcanceraphaseiistudyrotterdamoesophagealtumourstudygroup AT tilanushw cisplatinandetoposideinoesophagealcanceraphaseiistudyrotterdamoesophagealtumourstudygroup AT splinterta cisplatinandetoposideinoesophagealcanceraphaseiistudyrotterdamoesophagealtumourstudygroup |